The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) today affirmed a Patent Trial and Appeal Board (PTAB) ruling that ...

Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes.

SAN DIEGO, July 28, 2025--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter ...

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know.

DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Click here to read an analysis of DXCM stock now.

Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts.

Dexcom’s first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University ...

DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty.

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a defective speaker, after a number of the devices failed to provide audio alarms ...

DexCom, Inc. today reported its financial results as of and for the quarter ended March 31, 2025. "To start the year, Dexcom delivered a quarter of strong revenue results and unlocked significant ...